

Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study

Indra A. Van Assche, MSc¹; Evangeline A. Huis in 't Veld, MSc^{2,3}; Kristel Van Calsteren, MD, PhD^{1,4}; Mathilde van Gerwen, PhD^{2,3,5}; Jeroen Blommaert, PhD^{6,7,8}; Elyce Cardonick, MD, PhD⁹; Michael J. Halaska, MD, PhD¹⁰; Robert Fruscio, MD, PhD¹¹; Monica Fumagalli, MD, PhD^{12,13}; Jurgen Lemièr, PhD^{6,14}; Elisabeth M. van Dijk-Lokkart, PhD^{5,15}; Camilla Fontana, PhD¹³; Harm van Tinteren, PhD²; Jessie De Ridder, MD, PhD^{16,17}; Martine van Grotel, MD, PhD²; Marry M. van den Heuvel-Eibrink, MD, PhD^{2,18}; Lieven Lagae, MD, PhD^{1,16}; and Frédéric Amant, MD, PhD^{3,7,19}

abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; $P < .001$). No difference in FSIQ was found between treatment types ($F[4,140] = 0.45$, $P = .776$). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.

J Clin Oncol 41:1527-1532. © 2023 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License 

INTRODUCTION

Maternal cancer during pregnancy is an emerging challenge and may affect child development through both direct treatment effects and indirect environmental and psychosocial effects, in both prenatal and postnatal periods.¹ As part of the International Network on Cancer, Infertility and Pregnancy, our group previously published reports showing reassuring general outcomes of children prenatally exposed to maternal cancer and its treatment.²⁻⁷ Nevertheless, specific results highlight a need for continued follow-up. At a median age of 22 months, prematurity predicted poorer cognitive outcomes.^{2,3} At age 6 years, prenatally exposed children showed lower verbal intelligence and visuospatial long-term memory scores, and chemotherapy during pregnancy was associated with poorer emotional regulation.^{6,7} Maternal death also represented an important risk factor for poorer neurocognitive and behavioral outcomes.⁷⁻¹⁰

The question remains whether children born after a pregnancy complicated by maternal cancer are at risk of growing into deficits when complex cognitive and executive functions are developing and relying on brain structures that developed aberrantly during gestation and early childhood.^{11,12} This report describes the cognitive and behavioral outcomes of 9-year-old children prenatally exposed to maternal cancer and its treatment.

METHODS

Study Design

The INCIP Child Follow-up study (Protocol, online only) evaluates the general health and neurocognitive development after prenatal exposure to maternal cancer (treatment) using age-adapted standardized test batteries.⁷ Children are included longitudinally at the ages 18 months, 36 months, and subsequently once every 3 years until age 18 years.

ASSOCIATED CONTENT

Data Supplement Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on December 2, 2022 and published at ascopubs.org/journal/jco on January 12, 2023; DOI <https://doi.org/10.1200/JCO.22.02005>

TABLE 1. Demographic Characteristics of the Children

Characteristic	All Children (N = 151)	Children Prenatally Exposed to Chemotherapy (n = 109)
Cancer treatment during pregnancy, No. (%)		
Chemotherapy only	44 (29.1)	
Radiotherapy only	2 (1.3)	
Surgery only	18 (11.9)	
Chemotherapy and radiotherapy	2 (1.3)	
Chemotherapy and surgery	56 (37.1)	
Radiotherapy and surgery	5 (3.3)	
Chemotherapy, radiotherapy, and surgery	7 (4.6)	
Trastuzumab	1 (0.7)	
No treatment	16 (10.6)	
Chemotherapeutic agent type, No. (%) ^a		
Anthracyclines		86 (78.9)
Platinum		20 (18.3)
Taxanes		20 (18.3)
Vinca alkaloids		16 (14.7)
Other		4 (3.7)
Age, years, median (SD)	9.25 (0.39)	9.25 (0.39)
GA, weeks, median (SD)	36.12 (2.64)	35.77 (2.52)
Birth weight, g, mean (SD)	2,651.39 (622.62)	2,576.09 (613.71)
Maternal age at birth, years, mean (SD)	32.90 (4.52)	33.04 (4.16)
Sex, No. (%)		
Male	77 (51.0)	54 (49.5)
Female	74 (49.0)	55 (50.5)
Mother deceased, No. (%)		
Before age 2 years	16 (10.6)	13 (11.9)
After age 2 years	11 (7.3)	9 (8.3)
Not deceased	124 (82.1)	87 (79.8)
Highest level of education parents, No. (%) ^b		
Mother		
Primary school	5 (3.3)	2 (1.8)
Secondary school	58 (38.4)	45 (41.3)
Bachelor's degree	42 (27.8)	25 (22.9)
Master's degree or higher	36 (23.8)	27 (24.8)
Unknown	10 (6.6)	10 (9.2)
Father		
Primary school	6 (4.0)	3 (2.8)
Secondary school	57 (37.7)	40 (36.7)
Bachelor's degree	37 (24.5)	24 (22.0)
Master's degree or higher	33 (21.9)	26 (23.9)
Unknown	18 (11.9)	16 (14.7)

Abbreviations: GA, gestational age; SD, standard deviation.

^aSome children were exposed to multiple chemotherapeutic agent types, thus resulting in a total percentage > 100%.

^bThe highest level of education is presented according to the International Standard Classification of Education 2011,¹⁶ and recorded into four classes as done by Meekes et al.¹⁷ A bachelor's degree is earned at both traditional universities and nonuniversity institutions of higher education, and requires between 3 and 4 years of full-time study. A master's degree is earned at university, and requires 1-2 years of full-time study after a bachelor's degree.

We report a cross-sectional analysis of the 9-year-old children (Data Supplement, online only). Ethical approval and written informed consent was obtained for all participating subjects.

Outcomes

A neuropsychologic examination, assessing intelligence quotient, attention, memory, and behavior, was performed (Data Supplement). The primary outcome was the Full Scale Intelligence Quotient (FSIQ), derived from the Wechsler Intelligence Scale for Children.¹³⁻¹⁵ Secondary outcomes included all other neurocognitive test scores and behavioral questionnaire results. All children underwent a clinical neurologic and general pediatric examination, and parents completed a questionnaire on their child’s general health and educational level. All tests were conducted in the child’s native language.

Methodologic details are reported in the Data Supplement.

RESULTS

Participants

A total of 151 children (including seven pairs of twins) were included: 95 from Belgium, 34 from Netherlands, nine from Italy, six from Czech Republic, and seven from New Jersey (Table 1). The Data Supplement contains further information about maternal cancer types, treatment characteristics, substance use during pregnancy, fertility treatment, bilingualism, congenital malformations, and labor types and delivery modes.

Cognitive Development and Behavior

Group outcomes for all intelligence outcomes, verbal and visuospatial memory, attentional function, and behavioral measures were within normal ranges (Table 2 and Fig 1).

No difference in FSIQ was found between girls and boys ($t[143] = 0.25, P = .802$), treatment types ($F[4,140] = 0.45, P = .776$), or cancer stages ($F[3,140] = 1.53, P = .211$).

Children who scored below normal ranges were more likely to have been born preterm. The average FSIQ score increased by 1.6 points (95% CI, 0.7 to 2.5; $P < .001$; Data Supplement) for each week increase in gestational age at birth (GA). GA also explained verbal intelligence ($\beta = 1.49$ points/wk; CI, 0.6 to 2.4; $P = .002$), performance intelligence ($\beta = 1.39$ points/wk; CI, 0.6 to 2.2; $P = .002$), and processing speed ($\beta = 1.21$ points/wk; CI, 0.3 to 2.1; $P = .009$).

We found an effect of maternal bereavement ($F[2, 144] = 3.94, P = .022$). FSIQ was lower in children with a deceased mother before age 2 years (93.13 ± 12.65) than in children with a surviving mother (104.08 ± 14.88). When adjusting for GA, this association disappeared ($P > .3$): Children with a deceased mother before age 2 years were on average born earlier (33.4 weeks ± 2.7) than children with a deceased mother after age 2 years (37.1 weeks ± 1.7) and children with a surviving mother (36.4 weeks ± 2.5 ; $P < .001$). No associations were found between maternal death and cancer type, cancer stage, or treatment type.

TABLE 2. Means, SDs, and Ranges of Intelligence Scores

Intelligence Score	No.	Mean	SD	Range
Full-scale intelligence	145	102.84	14.99	60-141
Verbal intelligence	145	104.77	15.47	62-140
VCI (WISC-III/-IV/-V)	128			
VIQ (WISC-III) ^a	23			
Performance intelligence	145	101.72	14.19	62-141
POI (WISC-III)	44			
PRI (WISC-IV)	11			
VSI (WISC-V)	73			
PIQ (WISC-III) ^a	17			
Processing speed	129	101.35	14.21	66-146
Working memory	84	96.89	12.65	67-135

Abbreviations: IQ, intelligence quotient; PIQ, performance IQ; POI, Perceptual Organization Index; PRI, Perceptual Reasoning Index; VCI, Verbal Comprehension Index; VIQ, Verbal IQ; VSI, Visuospatial Index; WISC, Wechsler Intelligence Scale for Children.

^aVIQ and PIQ scores (from the WISC-III) were only included if VCI and POI scores, respectively, were not available.

Multiple linear regression (Data Supplement) with GA, death of mother, and parental (maternal and paternal) education level as explanatory variables shows that GA ($P = .006$) and maternal education level ($P = .005$) remained to explain FSIQ. Specifically, this model estimated an increase of 1.27 points (± 0.45) in FSIQ for every week increase in GA.

When looking specifically at the subgroup of children prenatally exposed to chemotherapy, a mixed-effect regression model, with parental education levels as random variables, found no significant associations with FSIQ (all $P > .08$). When parental education levels were separately included as fixed effects, maternal education level remained a significant predictor of FSIQ ($P = .011$).

General Health

Data from the parent-reported health questionnaire revealed no specific problems across the group. An overview of the reported medical problems is enlisted in the Data Supplement.

Four children were diagnosed with attention-deficit hyperactivity disorder, of which three took supportive medication. One child was diagnosed with autism spectrum disorder. Thirty-one children (24.4%) received remedial care, including speech therapy (17 children), remedial teaching at school (10), a type of physical or exercise therapy (four), and neurofeedback therapy (one).

From these children receiving remedial support, eight children (25.8%) lost their mother (of which seven before age 2 years), with a chi-squared test showing a significant relation between maternal bereavement before age 2 years and remedial care ($\chi^2 [2,127] = 7.33, P = .026, \phi = 0.240$). An association was also found between remedial support and




FIG 1. Cognitive (nonintelligence quotient) and behavioral outcomes. ANT, Amsterdam Neuropsychologic Task; AVLT, Auditory Verbal Learning Test; BRIEF, Behavior Rating Inventory of Executive Function; CBCL, Child Behavior Checklist; CMS, Children’s Memory Scale.

prematurity: 24 children (77.4%) who received remedial care were born preterm ($\chi^2 [1,127] = 6.67, P = .010, \phi = 0.229$).

DISCUSSION

Cognitive and behavioral outcomes of 9-year-old children born to mothers diagnosed with cancer during pregnancy did not differ with norms of the general population. We

reported average group scores for all intelligence index scores, verbal and visuospatial memory outcomes, attentional functioning outcomes, and behavioral questionnaire measures. We found no impact of sex, treatment type, and cancer stage.

Children who scored below normal ranges on intelligence index scores were more likely to have been born preterm.

We report an increase in Full Scale Intelligence Quotient of almost 6.5 points for each month increase in GA. Hence, preterm birth should be avoided as much as possible in the obstetric management of pregnant women with cancer.

Seventeen percent of the children in this study had lost their mother (of which almost 58% died before their child turned 2 years old). The results suggest a relationship between maternal bereavement in the first 1,000 days of life and Full Scale Intelligence, although a larger sample is necessary to disentangle effects of maternal loss and often coinciding premature birth.

A longitudinal study in the general population also demonstrates multicollinearity between the impact of early-life adversity exposure and prematurity.¹⁸ As maternal death was not associated with cancer type, cancer stage, or treatment type, it could be possible that maternal stress or an insecure mother-child attachment may play a role in determining child cognitive development.

In the subgroup of children prenatally exposed to chemotherapy, only maternal education level was associated with Full Scale Intelligence. In this group, no effect of prematurity was found in both the current 9-year-old cohort and the 6-year-old cohort.⁷ Further research is needed to determine whether the effect of prematurity is hidden by an underpowered analysis in the smaller chemotherapy group, or whether administering chemotherapy during pregnancy perhaps reduces the beneficial effect of delivery at term.

Maternal education level explained part of the outcome on Full Scale Intelligence. This effect was found in the entire sample

and chemotherapy subgroup. Although both paternal and maternal education level were associated with Full Scale Intelligence at the univariate level, only maternal education remained a significant predictor in fitted models.

Almost a quarter of parents reported a need for remedial support for their child. As rates of pediatric remedial support in the general population remain under-reported, disallowing a comparison of the observed rates and the rates of the general population, further research is needed to put this percentage in perspective. The need for remedial support may be related to prematurity and maternal bereavement, with 77% of the children who received support born preterm, and 26% of the children having lost their mother to cancer. In combination with a recent study showing increased child trauma-related cognitions and emotion regulation difficulties after parental cancer (bereavement),¹⁹ it tentatively supports the need to follow these families in the long term to determine their psychosocial needs.

In conclusion, children prenatally exposed to maternal cancer (treatment) showed on average a normal cognitive and behavioral development at age 9 years. No associations of cognition and behavior were found with treatment type, exposure level, cancer stage, and gestational age at the start of treatment. These results convey a reassuring follow-up of neurocognitive development during late childhood, which represents a time of critical maturation when complex functions are developing. However, these children still require a close follow-up, as maternal cancer during pregnancy is associated with preterm delivery and maternal death, which are risk factors for developmental problems.

AFFILIATIONS

¹Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium

²Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

³Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

⁴Division of Foetomaternal Medicine, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium

⁵Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands

⁶Department of Oncology, Unit of Pediatric Oncology, KU Leuven, Belgium

⁷Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Belgium

⁸Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Belgium

⁹Department of Obstetrics and Gynecology, Cooper University Health Care, Camden, NJ

¹⁰Department of Obstetric Gynecology, University Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czech Republic

¹¹Department of Medicine and Surgery, Clinic of Obstetrics and Gynecology, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy

¹²Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy

¹³Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milano, Italy

¹⁴Division of Pediatric Hemato-Oncology, Department of Pediatrics, UZ Leuven, Belgium

¹⁵Amsterdam Reproduction and Development, Child Development, Amsterdam, the Netherlands

¹⁶Division of Pediatric Neurology, Department of Pediatrics, UZ Leuven, Belgium

¹⁷Department of Development and Regeneration, Unit Locomotor and Neurological Disorders, KU Leuven, Belgium

¹⁸UMCU-Wilhelmina Children's Hospital, Utrecht, the Netherlands

¹⁹Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium

CORRESPONDING AUTHOR

Frédéric Amant, MD, PhD, Division of Gynecological Oncology, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium, Herestraat 49, 3000 Leuven, Belgium; e-mail: frederic.amant@uzleuven.be.

EQUAL CONTRIBUTION

I.A.V.A. and E.A.H.i.V. contributed equally to this work as co-first authors.

SUPPORT

I.A.V.A. is funded by Kom op Tegen Kanker (KOTK) as PhD researcher under the research project Cancer Treatment During Pregnancy, Grant No. ZKD6005. E.A.H.i.V. is funded by KWF Kankerbestrijding (KWF) as PhD researcher under the research project CRADLE-II, Grant No. 13192. J.B. is an aspirant researcher for the Research Foundation Flanders (FWO), Grant No. 11B9919N. KOTK, KWF, and FWO are independent nonprofit organizations and nongovernmental organizations for (cancer) research,

education, and support. M.J.H. was supported by Cooperatio program, Maternal and Childhood Care 207035, 3rd Faculty Medicine, Charles University. These organizations had no involvement in the idea, writing, editing of, or decision to submit this manuscript.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.22.02005>.

AUTHOR CONTRIBUTIONS

Conception and design: Indra A. Van Assche, Evangeline A. Huis in 't Veld, Kristel Van Calsteren, Michael J. Halaska, Harm van Tinteren, Marry M. van den Heuvel-Eibrink, Lieven Lagae, Frédéric Amant

Administrative support: Indra A. Van Assche, Evangeline A. Huis in 't Veld, Frédéric Amant

Provision of study materials or patients: Evangeline A. Huis in 't Veld, Kristel Van Calsteren, Mathilde van Gerwen, Robert Fruscio, Frédéric Amant

Collection and assembly of data: Indra A. Van Assche, Evangeline A. Huis in 't Veld, Kristel Van Calsteren, Mathilde van Gerwen, Elyce Cardonick, Michael J. Halaska, Robert Fruscio, Monica Fumagalli, Camilla Fontana,

Jessie De Ridder, Martine van Grotel, Marry M. van den Heuvel-Eibrink, Frédéric Amant

Data analysis and interpretation: Indra A. Van Assche, Evangeline A. Huis in 't Veld, Kristel Van Calsteren, Mathilde van Gerwen, Jeroen Blommaert, Michael J. Halaska, Robert Fruscio, Monica Fumagalli, Jurgen Lemiere, Elisabeth M. van Dijk-Lokkart, Camilla Fontana, Harm van Tinteren, Marry M. van den Heuvel-Eibrink, Frédéric Amant

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The authors thank the European Society of Gynaecological Oncology for their continued support. The authors are grateful to Matthew J. Dwyer, affiliated to the Rowan University of Glassboro, New Jersey, and to Jitka Zackova, affiliated to the Faculty Hospital Motol, for their efforts in performing neuropsychologic testing in the study children. The authors are also grateful to Diane Wolput, affiliated to UZ and KU Leuven, for collaborating with the child follow-up planning in Leuven, Belgium. The authors are also grateful to Rana Dandis, affiliated to the Princess Máxima Center for pediatric oncology, for her extended advice on the statistical analysis of the study.

REFERENCES

1. Van Assche IA, Lemiere J, Amant F, et al: Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy: What do we know so far? *Crit Rev Oncol Hematol* 179:103824, 2022
2. Amant F, Van Calsteren K, Halaska MJ, et al: Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study. *Lancet Oncol* 13:256-264, 2012
3. Amant F, Vandenbroucke T, Verheecke M, et al: Pediatric outcome after maternal cancer diagnosed during pregnancy. *N Engl J Med* 373:1824-1834, 2015
4. Blommaert J, Zink R, Deprez S, et al: Long-term impact of prenatal exposure to chemotherapy on executive functioning: An ERP study. *Clin Neurophysiol* 130:1655-1664, 2019
5. Blommaert J, Radwan A, Sleurs C, et al: The impact of cancer and chemotherapy during pregnancy on child neurodevelopment: A multimodal neuroimaging analysis. *EClinicalMedicine* 28:100598, 2020
6. van Gerwen M, Vandenbroucke T, Gorissen AS, et al: Executive functioning in 6 year old children exposed to chemotherapy in utero. *Early Hum Develop* 151:105198, 2020
7. Vandenbroucke T, Verheecke M, van Gerwen M, et al: Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. *Eur J Cancer* 138:57-67, 2020
8. Paksarian D, Eaton WW, Mortensen PB, et al: A population-based study of the risk of schizophrenia and bipolar disorder associated with parent-child separation during development. *Psychol Med* 45:2825-2837, 2015
9. Thomas AW, Caporale N, Wu C, et al: Early maternal separation impacts cognitive flexibility at the age of first independence in mice. *Dev Cogn Neurosci* 18:49-56, 2016
10. van Gerwen M, Huis in 't Veld E, van Grotel M, et al: Long-term neurodevelopmental outcome after prenatal exposure to maternal hematological malignancies with or without cytotoxic treatment. *Child Neuropsychol* 27:822-833, 2021
11. Sesma HW, Georgieff MK: The effect of adverse intrauterine and newborn environments on cognitive development: The experiences of premature delivery and diabetes during pregnancy. *Dev Psychopathol* 15:991-1015, 2003
12. Luciana M: Cognitive development in children born preterm: Implications for theories of brain plasticity following early injury. *Dev Psychopathol* 15:1017-1047, 2003
13. Wechsler D: WISC-V: Technical and Interpretive Manual. Bloomington, MN, Pearson, 2014
14. Wechsler D: Wechsler Intelligence Scale for Children (ed 3). San Antonio, TX, The Psychological Corporation, 1991
15. Wechsler D: Wechsler Intelligence Scale for Children—Fourth Edition (WISC-IV). San Antonio, TX, The Psychological Corporation, 2003
16. UNESCO Institute for Statistics: International Standard Classification of Education: ISCED 2011. Montreal, Quebec, Canada, UNESCO Institute for Statistics, 2012
17. Meekes J, van Schooneveld MMJ, Braams OB, et al: Parental education predicts change in intelligence quotient after childhood epilepsy surgery. *Epilepsia* 56:599-607, 2015
18. Turpin H, Urben S, Ansermet F, et al: The interplay between prematurity, maternal stress and children's intelligence quotient at age 11: A longitudinal study. *Sci Rep* 9:450, 2019
19. Egberts MR, Verkaik D, van Baar AL, et al: Child posttraumatic stress after parental cancer: Associations with individual and family factors. *J Pediatr Psychol* 47:1031-1043, 2022



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Jurgen Lemiere

Employment: Delta Clinics (I)

Lieven Lahaie

Honoraria: Zogenix/UCB (Inst), Novartis (Inst), Livanova (Inst)

Consulting or Advisory Role: UCB/Zogenix/Novartis/Eisai/Livanova (Inst)

Speakers' Bureau: UCB/Zogenix/Eisai/Jazz/Livanova (Inst)

Research Funding: Zogenix (Inst)

Patents, Royalties, Other Intellectual Property: Patent for fenfluramine in Dravet syndrome and infantile epilepsy (Inst)

Travel, Accommodations, Expenses: UCB/Zogenix/Livanova/Jazz (Inst)

Frédéric Amant

Honoraria: Roche

Consulting or Advisory Role: MiMark

No other potential conflicts of interest were reported.